BAD HOMBURG, Germany—Fresenius Medical Care AG announced that the U.S. Attorney's Office for the Eastern District of New York completed its investigation of the company’s North American subsidiaries.
No action will be taken against the company and its subsidiaries, including Spectra Renal Laboratories and Renal Care Group Inc. (RCG), which Fresenius Medical Care acquired by merger on March 31, 2006.
No allegations were filed against FME or RCG, nor were any fines, penalties or changes in policy or business practices requested. Fresenius Medical Care and Renal Care Group both received subpoenas in October 2004. Both companies cooperated fully with the investigation.
“We are pleased with the outcome of the investigation and the fact that it is now closed,” said Dr. Ben Lipps, CEO of Fresenius Medical Care and chairman of the management board said.
